Document is current

Article History

Received: 17 January 2025

Accepted: 27 May 2025

First Online: 13 June 2025

Competing interests

: G.V. reports research funding from Gilead Sciences, and travel expenses, honoraria and/or advisory board roles from Gilead Sciences, Janssen, and EMD Serono. L.N. has served on advisory boards and/or received honoraria from AstraZeneca, Bayer, Eisai, EMD-Serono, Ipsen, Janssen, Merck, Novartis, Pfizer, TerSera. C.M.D. reports Honoria from MSD, Bristol-Myers Squibb, Medison and Pfizer and consulting fees from Biomica LTD. K.N.C. reports grants from Janssen, Astellas, and Sanofi during the conduct of the study. K.N.C. also reports grants and personal fees from Janssen, Astellas, AstraZeneca, and Sanofi, as well as personal fees from Constellation Pharmaceuticals, Daiichi Sankyo, Merck, Novartis, Pfizer, Point Biopharma, and Roche outside the submitted work. B.J.E. reports honoraria from Seagen, EMD Serono, Pfizer, Janssen, BMS, Gilead, Merck, LOXO-Lilly and AstraZeneca. Maryam.S. has served on advisory boards and/or received honoraria from Pfizer, Ipsen, Novartis, Bayer, AstraZeneca, Alpha-9 Oncology, consulting fees from Bayer, Ipsen, Novartis and Eisai Limited, and travel support from Ipsen and Pfizer. A.W.W. has served on advisory boards and/or received honoraria from AstraZeneca, Astellas, Bayer, EMD Serono, Janssen, Merck, and Pfizer. A.W.W.’s laboratory has a contract research agreement with ESSA Pharma, Tyra Biosciences, and Promontory Therapeutics. The remaining authors declare no competing interests.